Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
46
OMIC Quote, Financials, Valuation and Earnings
Last price:
$19.36
Seasonality move
:
-26.94%
Day range:
$19.26 - $19.66
52-week range:
$5.34 - $23.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
18.02x
P/B ratio:
0.39x
Volume:
18.6K
Avg. volume:
17.8K
1-year change:
50.35%
Market cap:
$48.6M
Revenue:
$2.9M
EPS (TTM):
-$34.76
Analysts' Opinion
-
Consensus RatingSingular Genomics Systems has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Singular Genomics Systems has an estimated downside of -35.66% from its current price of $19.35.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $19.35.
Fair Value
-
According to the consensus of 2 analysts, Singular Genomics Systems has -35.66% downside to fair value with a price target of -- per share.
OMIC vs. S&P 500
-
Over the past 5 trading days, Singular Genomics Systems has underperformed the S&P 500 by -4.64% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Singular Genomics Systems does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Singular Genomics Systems revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Singular Genomics Systems reported revenues of $406K.
Earnings Growth
-
Singular Genomics Systems has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Singular Genomics Systems reported earnings per share of -$6.72.
Enterprise value:
-60.1M
EV / Invested capital:
-0.47x
Price / LTM sales:
18.02x
EV / EBIT:
--
EV / Revenue:
-22.53x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.74x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.4M
Return On Assets:
-36.1%
Net Income Margin (TTM):
-3237.89%
Return On Equity:
-54.24%
Return On Invested Capital:
-51.76%
Operating Margin:
-4450.99%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $2.6M | $2.7M | $462K | $406K | |
| Gross Profit | -- | -$125K | -$1.4M | -$65K | -$301K | |
| Operating Income | -$90.6M | -$100.1M | -$93M | -$24.5M | -$18.1M | |
| EBITDA | -$84.2M | -$84.3M | -$78.3M | -$20.2M | -$14.8M | |
| Diluted EPS | -$37.50 | -$38.43 | -$34.76 | -$9.25 | -$6.72 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $364.2M | $286.1M | $210.8M | $129.8M | |
| Total Assets | -- | $370.8M | $345.5M | $284.5M | $186.6M | |
| Current Liabilities | -- | $6M | $14.2M | $15.5M | $17.6M | |
| Total Liabilities | -- | $18.8M | $68.6M | $85.5M | $63.3M | |
| Total Equity | -- | $352.1M | $276.9M | $199M | $123.3M | |
| Total Debt | -- | -- | -- | $10.2M | $5.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$82.9M | -$74.7M | -$80.4M | -$16.8M | -$19.8M | |
| Cash From Investing | -$63.1M | $13.3M | $98.5M | -$24.7M | $42.3M | |
| Cash From Financing | $961K | $1.4M | $152K | -- | -- | |
| Free Cash Flow | -$88.9M | -$77.1M | -$80.9M | -$16.9M | -$19.8M | |
OMIC
Sector
Market Cap
$48.6M
$46.1M
Price % of 52-Week High
82.66%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
3.62%
-0.6%
1-Year Price Total Return
50.35%
-30.52%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$19.69
200-day SMA
Buy
Level
$13.08
Bollinger Bands (100)
Buy
Level
8.93 - 20.71
Chaikin Money Flow
Sell
Level
-17.6M
20-day SMA
Sell
Level
$20.39
Relative Strength Index (RSI14)
Sell
Level
44.20
ADX Line
Sell
Level
17.64
Williams %R
Buy
Level
-85
50-day SMA
Buy
Level
$19.24
MACD (12, 26)
Sell
Level
-0.13
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Sell
Level
-5.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.9124)
Sell
CA Score
(Annual)
Level (-0.7826)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (1.8218)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.
Stock Forecast FAQ
In the current month, OMIC has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The OMIC average analyst price target in the past 3 months is --.
-
Where Will Singular Genomics Systems Stock Be In 1 Year?
According to analysts, the consensus estimate is that Singular Genomics Systems share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Singular Genomics Systems?
Analysts are divided on their view about Singular Genomics Systems share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Singular Genomics Systems is a Sell and believe this share price will rise from its current level to --.
-
What Is Singular Genomics Systems's Price Target?
The price target for Singular Genomics Systems over the next 1-year time period is forecast to be -- according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is OMIC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Singular Genomics Systems is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of OMIC?
You can purchase shares of Singular Genomics Systems via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Singular Genomics Systems shares.
-
What Is The Singular Genomics Systems Share Price Today?
Singular Genomics Systems was last trading at $19.36 per share. This represents the most recent stock quote for Singular Genomics Systems. Yesterday, Singular Genomics Systems closed at $19.35 per share.
-
How To Buy Singular Genomics Systems Stock Online?
In order to purchase Singular Genomics Systems stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
